TLR9-activating cholesterol azetidine derivative-assisted therapeutic vaccines for cancer immunotherapy - PubMed
3 hours ago
- #TLR9 activation
- #therapeutic vaccines
- #cancer immunotherapy
- Therapeutic cancer vaccines show promise but face challenges in coordinating innate immune activation and antigen delivery.
- Aze-Chol NP, a cholesterol azetidine derivative-assisted polymeric carrier, activates dendritic cells via the TLR9 pathway and delivers antigens to lymph nodes.
- Aze-Chol NP-based nanovaccines significantly inhibited tumor growth and prolonged survival in melanoma and HPV tumor models.
- Combining the nanovaccine with an anti-PD-L1 antibody resulted in an 80% survival rate beyond 100 days and complete tumor rejection upon rechallenge.
- The study demonstrates that TLR9-activating carriers like Aze-Chol NP offer an effective strategy for developing potent cancer vaccines.